BiotechTube

1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo

Phase 3Recruiting
1 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Developmental and Epileptic Encephalopathy 1

Conditions

Developmental and Epileptic Encephalopathy 1

Trial Timeline

Jul 9, 2025 → Jul 1, 2027

NCT ID
NCT07010471

About 1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo

1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo is a phase 3 stage product being developed by Praxis Precision Medicines for Developmental and Epileptic Encephalopathy 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07010471. Target conditions include Developmental and Epileptic Encephalopathy 1.

What happened to similar drugs?

0 of 1 similar drugs in Developmental and Epileptic Encephalopathy 1 were approved

Approved (0) Terminated (0) Active (1)
🔄Aripiprazole oral product + Placebo oral capsuleBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07010471Phase 3Recruiting

Competing Products

4 competing products in Developmental and Epileptic Encephalopathy 1

See all competitors
ProductCompanyStageHype Score
Aripiprazole oral product + Placebo oral capsuleBristol Myers SquibbPhase 3
40
NBI-921352 + PlaceboNeurocrine BiosciencesPhase 2
24
NBI-921352Neurocrine BiosciencesPhase 2
36
SertralineBrain BiotechPhase 2
32